Use of inosine pranobex in frequently ill children

The follow-up group of «frequently ill children» is formed on the basis of criteria formulated by domestic pediatricians A.A. Baranov and V.Yu. Al’bitskiy, due to the high relevance of medical, social and economic problems caused by the increased morbidity in this category of patients especially with acute respiratory infections, with likely development of severe complications or the manifestation of chronic respiratory diseases. In general, the state of the immune system in frequently ill children is characterized by decreased local immunity and increased stress of systemic immunity, and the features of the functional immunity activity in this category of patients determine the various possibilities to affect immunity during the prevention and treatment of acute respiratory infections. This article discusses the features of the functional activity of the immune system in frequently ill children, as well as the possibilities of drug management of its disorders and the benefits of using inosine pranobex to prevent and treat respiratory infections in this category of patients. According to the international classification of drugs maintained by the World Health Organization, the drug belongs to the groups of immunomodulators (L) and antimicrobial antiviral drugs (J) for systemic use. It is proved that inosine pranobex effectively increases cellular and humoral immunity, and reduces non-specifically the viral replication capacity. During clinical trials, the drug proved to be a highly effective and safe component of the complex treatment of acute respiratory infections in frequently ill children. The use of inosine pranobex reduces the duration and intensity of symptoms of infectious respiratory tract diseases. The drug can be recommended for children with concomitant chronic respiratory tract diseases.

1. Kotlukov V.K., Kuz’menko L.G. Rational antibiotic therapy of the respiratory tract infections and ENT organs in children in the outpatient paediatric practice. Pediatriya = Pediatria. 2008;87(6). (In Russ.) Available at: http://pediatriajournal.ru/archive?show=295&section=2264.

2. Simonova O.I., Lazareva A.V., Motuzova O.V., Ponamorenko O.A., Katosova L.K., Chistyakova V.P., Burkina N.I. New possibilities of antibacterial treatment in acute and chronic respiratory disorders in children. Voprosy sovremennoj pediatri = Current Pediatrics. 2013;12(1):123-130. (In Russ.) doi: 10.15690/vsp.v12i1.568.

3. Germanova O.N., Golubeva M.V., Baricheva L.Y. Bronchial obstruction in children with respiratory tract infections. Meditsinskiy vestnik Severnogo Kavkaza = Medical news of the north caucasus. 2010;(4):42-47. (In Russ.) Available at: https://medvestnik.stgmu.ru/files/medvestnik_2010_4.pdf.

4. Savenkova M.S., Abdulaev A.K., Afanasyeva A.A., Minasyan V.S., Tjurkina S.I. Sickly children: aethilogy and treatment 20 years later. Detskie infekcii = Children infections. (In Russ). 2009;(4):27-34. (In Russ.) Available at: https://elibrary.ru/item.asp?id=13019593.

5. Voznesenskaya N.I., Margieva T.V. Acute respiratory infections in children – a tactics choice. Pediatričeskaa farmakologia = Pediatric pharmacology. 2011;8(2):102-106. (In Russ.) Available at: https://elibrary.ru/item.asp?id=16256820.

6. Namazova L., Tatochenko V., Aleksina S., Galitskaya M., Izvol’skaya Z., Fedoseenko M., Voznesenskaya N. Vaccination against flu, pneumococcal, meningococcal and hib infection of the sickly children. Pediatričeskaa farmakologia = Pediatric pharmacology. 2007;4(1):6881. (In Russ.) Available at: https://pf.spr-journal.ru/jour/article/view/630.

7. Al’bitskiy V. Yu., Baranov A. A. Frequently ill children. Clinical and social aspects, ways of health improvement. Saratov: Saratov University; 1986. 184 p. (In Russ.)

8. Korovina N.A., Zaplatnikov A.L., Cheburkin A.V., Zakharova I.N. Frequently and chronically ill children: current possibilities for immunorehabilitation. A guide for doctors. Moscow: Contimed; 2011, 68 p. (In Russ.)

9. Herrod H.G. Follow-up of pediatric patients with recurrent infection and mild serologic immune abnormalities. Ann. Allergy Asthma Immunol. 1997;79(5):460–464. doi: 10.1016/S1081-1206(10)63044-X.

10. Kladova O.V. Immunopathogenesis, clinic presentation and treatment of recurrent croupous pneumonia in children: extended abstract of Dr. of Sci. (Med.) dissertation. Moscow. 2003. (In Russ.) Available at: http://medical-diss.com/docreader/246859/d?#?page=1.

11. Kladova O.V., Zamakhina E.V., Butakova E.P., Bazanova A.S., Legkova T.P., Feldfix L., Uchaykin V.F. The functional condition of immune Tand B-cells in infants/children suffering from frequent respiratory infectious diseases. Detskie infekcii = Children infections. 2009;(2):15-19. (In Russ.) Available at: https://elibrary.ru/item.asp?id=12845099.

12. Alsharifi M., Mullbacher A., Regner M. Interferon type-I responses in primary and secondary infections. Immunol. Cell Biology. 2008;86(3):239-245. doi: 10.1038/sj.icb.7100159.

13. Ershov F. I. Antiviral drugs. Moscow: Medicine; 1998, 192 p. (In Russ.)

14. Golebiowska-Wawrzyniak M., Markiewicz K., Kozar A., Derentowicz P., Czerwińska-Kartowicz I., Jastrzebska-Janas K., Wacławek J., Wawrzyniak Z.M., Siwińska-Gołebiowska H. Immunological and clinical study on therapeutic efficiacy of inosine pranobex. Pol. Merkuriusc. Lek. 2005;(19):379–382. Available at: https://www.ncbi.nlm.nih.gov/pubmed/16358878.

15. Osidak L.V., Zarubaev V.V., Obraztsova E.V., Erman E.S., Drinevsky V.P. Isoprinosin in therapy of acute respiratory viral infections in frequently ill children. Detskie infekcii = Children infections. 2008;(4):35-41. (In Russ.) Available at: https://elibrary.ru/item.asp?id=11667207.

16. Petrova M., Jelev D., Ivanova A., Krastev Z. Isoprinosine affects serum cytokine levels in healthy adults. J Interferon Cytokine Res. 2010;30(4):223–228. doi: 10.1089/jir.2009.0057.

17. Ahmed R.S., Newman A.S., O’Daly J., Duffy S., Grafton G., Brady C.A., Curnow J.S., Barnes N.M., Gordon J. Inosine acedoben dimepranol promotes an early and sustained increase in the natural killer cell component of circulating lymphocytes: a clinical trial supporting antiviral indications. Int Immunopharmacol. 2017;(42):108–114. doi: 10.1016/j.intimp.2016.11.023.

18. Lasek W., Janyst M., Wolny R., Zapała Ł., Bocian K., Drela N. Immunomodulatory effects of inosine pranobex on cytokine production by human lymphocytes. Acta Pharm. 2015;65(2):171-180. doi: 10.1515/acph-2015-0015.

19. Campoli-Richards D.M., Sorkin E.M., Heel R.C. Inosine pranobex. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy. Drugs. 1986:32(5):383–424. doi: 10.2165/00003495198632050-00001.

20. You Y., Wang L., Li Y., Wang Q., Cao S., Tu Y., Li S., Bai L., Lu J., Wei Z., Chen W., Hao F. Multicenter randomized study of inosine pranobex versus acyclovir in the treatment of recurrent herpes labialis and recurrent herpes genitalis in Chinese patients. J Dermatol. 2015;42(6):596– 601. doi: 10.1111/1346-8138.12845.

21. Osidak L.V., Obraztsova E.V. Study results of inosine pranobex medication inclusion into therapy of acute respiratory viral infections in children. Lechashchiy vrach = Attending Physician. 2012;(10):1-4. (In Russ.) Available at: https://www.lvrach.ru/2012/10/15435569/.

22. Shamsheva O.V., Boytsov V.P. Experience of application of different inozine pranobex courses in ARVI (acute respiratory viral infection) and flu therapy in children. Lechashchiy vrach = Attending Physician. 2013;(8):92-95. (In Russ.) Available at: https://www.lvrach.ru/2013/08/15435790/.